Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:TCON

TRACON Pharmaceuticals (TCON) Stock Price, News & Analysis

TRACON Pharmaceuticals logo

About TRACON Pharmaceuticals Stock (NASDAQ:TCON)

Advanced Chart

Key Stats

Today's Range
$0.03
$0.05
50-Day Range
$0.02
$0.08
52-Week Range
$0.00
$14.75
Volume
23,886 shs
Average Volume
120,908 shs
Market Capitalization
$109.80 thousand
P/E Ratio
0.01
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive TCON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TRACON Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TCON Stock News Headlines

A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
Q1 2024 TRACON Pharmaceuticals Inc Earnings Call
See More Headlines

TCON Stock Analysis - Frequently Asked Questions

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) posted its quarterly earnings results on Tuesday, May, 14th. The biopharmaceutical company reported ($1.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by $0.13. The biopharmaceutical company had revenue of $0.10 million for the quarter.

TRACON Pharmaceuticals shares reverse split on Wednesday, April 10th 2024.The 1-20 reverse split was announced on Wednesday, April 10th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 10th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

TRACON Pharmaceuticals (TCON) raised $47 million in an initial public offering (IPO) on Friday, January 30th 2015. The company issued 3,600,000 shares at a price of $12.00-$14.00 per share. Wells Fargo Securities and Stifel served as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that TRACON Pharmaceuticals investors own include NVIDIA (NVDA), SCYNEXIS (SCYX), Micron Technology (MU), Advanced Micro Devices (AMD), OPKO Health (OPK), Taiwan Semiconductor Manufacturing (TSM) and Meta Platforms (META).

Company Calendar

Last Earnings
5/14/2024
Today
7/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TCON
Employees
20
Year Founded
N/A

Profitability

Trailing P/E Ratio
0.01
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$3.59 million
Pretax Margin
145.93%

Debt

Sales & Book Value

Annual Sales
$12.05 million
Cash Flow
$1.61 per share
Price / Cash Flow
0.02
Book Value
($0.37) per share
Price / Book
-0.09

Miscellaneous

Free Float
3,228,000
Market Cap
$109.80 thousand
Optionable
No Data
Beta
1.37

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:TCON) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners